MAPT and Alzheimer disease: Recently, it is found that ROCK inhibitors decrease the p-tau in an AD model for tauopathies, and inhibition of Rho/ROCK pathway is able to activate autophagy and proteasome to degrade tau proteins through inactivating glycogen synthase kinase 3β, cyclin-dependent kinase 5, and caspase and further activating protein phosphatase 2A(Hamano et al. 2020).